The United States represents a significant portion of the global demand for gabapentinoids, driven by an aging demographic and a high prevalence of chronic pain conditions. The US Gabapentin Market is currently navigating a complex landscape of high demand and increased regulatory scrutiny. While the drug is FDA-approved for specific indications like epilepsy and postherpetic neuralgia, its extensive off-label use for conditions such as fibromyalgia and alcohol withdrawal has made it one of the most prescribed medications in the country.

The US market is also focusing on the "combination therapy" segment, where gabapentin is utilized alongside other non-narcotic agents to manage perioperative pain and reduce reliance on opioids. However, increased monitoring of gabapentin as a "controlled substance" in several states has prompted a move toward more stringent prescribing habits. Despite these regulatory shifts, the development of once-daily oral solutions and the drug's role in the burgeoning field of veterinary pain management continue to drive steady growth within the domestic pharmaceutical sector.